Status:

COMPLETED

Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women

Lead Sponsor:

Novartis

Conditions:

Forearm Fracture

Eligibility:

FEMALE

60+ years

Phase:

PHASE4

Brief Summary

Calcitonin has been used for many years for treating osteoporosis in postmenopausal women, and it has been shown that calcitonin reduces pain after spine and hip fracture in women with osteoporosis. T...

Eligibility Criteria

Inclusion

  • Post-menopausal women, aged at least 60 years old
  • Having a forearm fracture within the last 3-7 days before treatment
  • Fracture is treated with either a plaster cast only, or a cast plus Kirschner wires

Exclusion

  • Multiple fractures, severe fractures, or the forearm fractured in more than one place
  • Nerve damage in the forearm caused by the fracture
  • Other conditions which would interfere with the grip strength measurements (e.g. swelling, paralysis, skin diseases or rheumatoid arthritis)
  • Other protocol-defined inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

March 1 2002

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT00239889

Start Date

March 1 2002

Last Update

November 30 2006

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Novartis

Nuremberg, Germany

2

Novartis

Basel, Switzerland

Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women | DecenTrialz